TLR7 signaling regulates Th17 cells and autoimmunity: Novel potential for autoimmune therapy

Journal of Immunology

Volumn 199, Issue 3, 2017, Pages 941-954

  Ye, Jian ^a   Wang, Yadan ^a   Liu, Xia ^a   Li, Lingyun ^a   Opejin, Adeleye ^a   Hsueh, Eddy C ^a   Luo, Huanle ^b   Wang, Tian ^b   Hawiger, Daniel ^a   Peng, Guangyong ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMIQUIMOD; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; MYELOID DIFFERENTIATION FACTOR 88; STAT3 PROTEIN; STAT5 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; TOLL LIKE RECEPTOR 7; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR GATA 3; TUMOR NECROSIS FACTOR; AMINOQUINOLINE DERIVATIVE; MEMBRANE PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING; TLR7 PROTEIN, HUMAN; TLR7 PROTEIN, MOUSE;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CANCER CELL; CD4+ T LYMPHOCYTE; CELL COUNT; CELL DIFFERENTIATION; CELL INFILTRATION; CELL INTERACTION; CELL POPULATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DISEASE SEVERITY; DOWN REGULATION; DRUG EFFICACY; DRUG RESPONSE; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; GENE EXPRESSION; HUMAN; HUMAN CELL; IL 17 GENE; IMMUNIZATION; IMMUNOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN FUNCTION; RNA STABILITY; RNA SYNTHESIS; TH1 CELL; TH17 CELL; TRANSCRIPTION REGULATION; ANIMAL; BIOSYNTHESIS; DISEASE MODEL; DRUG EFFECTS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; GENETICS; IMMUNOLOGY; INFLAMMATION; METABOLISM; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION;

AMINOQUINOLINES; ANIMALS; AUTOIMMUNITY; CELL DIFFERENTIATION; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; IMMUNOTHERAPY; INFLAMMATION; INTERLEUKIN-17; MEMBRANE GLYCOPROTEINS; MICE; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TH1 CELLS; TH17 CELLS; TOLL-LIKE RECEPTOR 7;

EID: 85026209468     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1601890     Document Type: Article

References (63)

1. Bettelli, E., T. Korn, and V. K. Kuchroo. 2007. Th17: the third member of the effector T cell trilogy. Curr. Opin. Immunol. 19: 652-657
2. Tesmer, L. A., S. K. Lundy, S. Sarkar, and D. A. Fox. 2008. Th17 cells in human disease. Immunol. Rev. 223: 87-113
3. Dandekar, S., M. D. George, and A. J. Bäumler. 2010. Th17 cells, HIV and the gut mucosal barrier. Curr. Opin. HIV AIDS 5: 173-178
4. Ye, J., X. Su, E. C. Hsueh, Y. Zhang, J. M. Koenig, D. F. Hoft, and G. Peng. 2011. Human tumor-infiltrating Th17 cells have the capacity to differentiate into IFN-g+ and FOXP3+ T cells with potent suppressive function. Eur. J. Immunol. 41: 936-951
5. Su, X., J. Ye, E. C. Hsueh, Y. Zhang, D. F. Hoft, and G. Peng. 2010. Tumor microenvironments direct the recruitment and expansion of human Th17 cells. J. Immunol. 184: 1630-1641
6. Ye, J., R. S. Livergood, and G. Peng. 2013. The role and regulation of human Th17 cells in tumor immunity. Am. J. Pathol. 182: 10-20
7. Zou, W., and N. P. Restifo. 2010. T(H)17 cells in tumour immunity and immunotherapy. Nat. Rev. Immunol. 10: 248-256
8. Mangan, P. R., L. E. Harrington, D. B. O'Quinn, W. S. Helms, D. C. Bullard, C. O. Elson, R. D. Hatton, S. M. Wahl, T. R. Schoeb, and C. T. Weaver. 2006. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 441: 231-234
9. Korn, T., E. Bettelli, W. Gao, A. Awasthi, A. Jäger, T. B. Strom, M. Oukka, and V. K. Kuchroo. 2007. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 448: 484-487
10. Zhou, L., I. I. Ivanov, R. Spolski, R. Min, K. Shenderov, T. Egawa, D. E. Levy, W. J. Leonard, and D. R. Littman. 2007. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat. Immunol. 8: 967-974
11. Wilson, N. J., K. Boniface, J. R. Chan, B. S. McKenzie, W. M. Blumenschein, J. D. Mattson, B. Basham, K. Smith, T. Chen, F. Morel, et al. 2007. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat. Immunol. 8: 950-957
12. Ivanov, I. I., B. S. McKenzie, L. Zhou, C. E. Tadokoro, A. Lepelley, J. J. Lafaille, D. J. Cua, and D. R. Littman. 2006. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 126: 1121-1133
13. Chen, Q., W. Yang, S. Gupta, P. Biswas, P. Smith, G. Bhagat, and A. B. Pernis. 2008. IRF-4-binding protein inhibits interleukin-17 and interleukin-21 production by controlling the activity of IRF-4 transcription factor. Immunity 29: 899-911
14. Shi, L. Z., R. Wang, G. Huang, P. Vogel, G. Neale, D. R. Green, and H. Chi. 2011. HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells. J. Exp. Med. 208: 1367-1376
15. Kawai, T., and S. Akira. 2010. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 11: 373-384
16. Reynolds, J. M., B. P. Pappu, J. Peng, G. J. Martinez, Y. Zhang, Y. Chung, L. Ma, X. O. Yang, R. I. Nurieva, Q. Tian, and C. Dong. 2010. Toll-like receptor 2 signaling in CD4(+) T lymphocytes promotes T helper 17 responses and regulates the pathogenesis of autoimmune disease. Immunity 32: 692-702
17. Shi, G., B. P. Vistica, L. F. Nugent, C. Tan, E. F. Wawrousek, D. M. Klinman, and I. Gery. 2013. Differential involvement of Th1 and Th17 in pathogenic autoimmune processes triggered by different TLR ligands. J. Immunol. 191: 415-423
18. Reynolds, J. M., G. J. Martinez, Y. Chung, and C. Dong. 2012. Toll-like receptor 4 signaling in T cells promotes autoimmune inflammation. Proc. Natl. Acad. Sci. USA 109: 13064-13069
19. Peng, G., Z. Guo, Y. Kiniwa, K. S. Voo, W. Peng, T. Fu, D. Y. Wang, Y. Li, H. Y.Wang, and R. F.Wang. 2005. Toll-like receptor 8-mediated reversal of CD4 + regulatory T cell function. Science 309: 1380-1384
20. Kiniwa, Y., Y. Miyahara, H. Y. Wang, W. Peng, G. Peng, T. M. Wheeler, T. C. Thompson, L. J. Old, and R. F. Wang. 2007. CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer. Clin. Cancer Res. 13: 6947-6958
21. Peng, G., H. Y. Wang, W. Peng, Y. Kiniwa, K. H. Seo, and R. F. Wang. 2007. Tumor-infiltrating gammadelta T cells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway. Immunity 27: 334-348
22. Ye, J., X. Huang, E. C. Hsueh, Q. Zhang, C. Ma, Y. Zhang, M. A. Varvares, D. F. Hoft, and G. Peng. 2012. Human regulatory T cells induce T-lymphocyte senescence. Blood 120: 2021-2031
23. Ye, J., C. Ma, E. C. Hsueh, C. S. Eickhoff, Y. Zhang, M. A. Varvares, D. F. Hoft, and G. Peng. 2013. Tumor-derived gd regulatory T cells suppress innate and adaptive immunity through the induction of immunosenescence. J. Immunol. 190: 2403-2414
24. Paulos, C. M., A. Kaiser, C. Wrzesinski, C. S. Hinrichs, L. Cassard, A. Boni, P. Muranski, L. Sanchez-Perez, D. C. Palmer, Z. Yu, et al. 2007. Toll-like receptors in tumor immunotherapy. Clin. Cancer Res. 13: 5280-5289
25. Smits, E. L., P. Ponsaerts, Z. N. Berneman, and V. F. Van Tendeloo. 2008. The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy. Oncologist 13: 859-875
26. Sospedra, M., and R. Martin. 2005. Immunology of multiple sclerosis. Annu. Rev. Immunol. 23: 683-747
27. Bettelli, E., M. Oukka, and V. K. Kuchroo. 2007. T(H)-17 cells in the circle of immunity and autoimmunity. Nat. Immunol. 8: 345-350
28. O'Brien, K., D. C. Fitzgerald, K. Naiken, K. R. Alugupalli, A. M. Rostami, and B. Gran. 2008. Role of the innate immune system in autoimmune inflammatory demyelination. Curr. Med. Chem. 15: 1105-1115
29. Prinz, M., F. Garbe, H. Schmidt, A. Mildner, I. Gutcher, K. Wolter, M. Piesche, R. Schroers, E. Weiss, C. J. Kirschning, et al. 2006. Innate immunity mediated by TLR9 modulates pathogenicity in an animal model of multiple sclerosis. J. Clin. Invest. 116: 456-464
30. Visser, L., H. Jan de Heer, L. A. Boven, D. van Riel, M. van Meurs, M. J. Melief, U. Zähringer, J. van Strijp, B. N. Lambrecht, E. E. Nieuwenhuis, and J. D. Laman. 2005. Proinflammatory bacterial peptidoglycan as a cofactor for the development of central nervous system autoimmune disease. J. Immunol. 174: 808-816
31. Touil, T., D. Fitzgerald, G. X. Zhang, A. Rostami, and B. Gran. 2006. Cutting edge: TLR3 stimulation suppresses experimental autoimmune encephalomyelitis by inducing endogenous IFN-beta. J. Immunol. 177: 7505-7509
32. Hayashi, T., C. S. Gray, M. Chan, R. I. Tawatao, L. Ronacher, M. A. McGargill, S. K. Datta, D. A. Carson, and M. Corr. 2009. Prevention of autoimmune disease by induction of tolerance to toll-like receptor 7. Proc. Natl. Acad. Sci. USA 106: 2764-2769
33. O'Brien, K., D. Fitzgerald, A. Rostami, and B. Gran. 2010. The TLR7 agonist, imiquimod, increases IFN-beta production and reduces the severity of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 221: 107-111
34. Vultaggio, A., F. Nencini, S. Pratesi, L. Maggi, A. Guarna, F. Annunziato, S. Romagnani, P. Parronchi, and E. Maggi. 2011. The TLR7 ligand 9-benzyl-2- butoxy-8-hydroxy adenine inhibits IL-17 response by eliciting IL-10 and IL-10- inducing cytokines. J. Immunol. 186: 4707-4715
35. Yu, C. F., W. M. Peng, J. Oldenburg, J. Hoch, T. Bieber, A. Limmer, G. Hartmann, W. Barchet, A. M. Eis-Hübinger, and N. Novak. 2010. Human plasmacytoid dendritic cells support Th17 cell effector function in response to TLR7 ligation. J. Immunol. 184: 1159-1167
36. Lombardi, V., L. Van Overtvelt, S. Horiot, and P. Moingeon. 2009. Human dendritic cells stimulated via TLR7 and/or TLR8 induce the sequential production of Il-10, IFN-gamma, and IL-17A by naive CD4+ T cells. J. Immunol. 182: 3372-3379
37. Kattah, M. G., M. T. Wong, M. D. Yocum, and P. J. Utz. 2008. Cytokines secreted in response to Toll-like receptor ligand stimulation modulate differentiation of human Th17 cells. Arthritis Rheum. 58: 1619-1629
38. Dzopalic, T., A. Dragicevic, S. Vasilijic, D. Vucevic, I. Majstorovic, B. Bozic, B. Balint, and M. Colic. 2010. Loxoribine, a selective Toll-like receptor 7 agonist, induces maturation of human monocyte-derived dendritic cells and stimulates their Th-1- and Th-17-polarizing capability. Int. Immunopharmacol. 10: 1428-1433
39. Pham, N. L., V. P. Badovinac, and J. T. Harty. 2009. A default pathway of memory CD8 T cell differentiation after dendritic cell immunization is deflected by encounter with inflammatory cytokines during antigen-driven proliferation. J. Immunol. 183: 2337-2348
40. Liu, X. K., X. Lin, and S. L. Gaffen. 2004. Crucial role for nuclear factor of activated T cells in T cell receptor-mediated regulation of human interleukin-17. J. Biol. Chem. 279: 52762-52771
41. Henderson, J. G., A. Opejin, A. Jones, C. Gross, and D. Hawiger. 2015. CD5 instructs extrathymic regulatory T cell development in response to self and tolerizing antigens. Immunity 42: 471-483
42. Ye, J., C. Ma, E. C. Hsueh, J. Dou, W. Mo, S. Liu, B. Han, Y. Huang, Y. Zhang, M. A. Varvares, et al. 2014. TLR8 signaling enhances tumor immunity by preventing tumor-induced T-cell senescence. EMBO Mol. Med. 6: 1294-1311
43. Fukata, M., K. Breglio, A. Chen, A. S. Vamadevan, T. Goo, D. Hsu, D. Conduah, R. Xu, and M. T. Abreu. 2008. The myeloid differentiation factor 88 (MyD88) is required for CD4+ T cell effector function in a murine model of inflammatory bowel disease. J. Immunol. 180: 1886-1894
44. Tomita, T., T. Kanai, T. Fujii, Y. Nemoto, R. Okamoto, K. Tsuchiya, T. Totsuka, N. Sakamoto, S. Akira, and M. Watanabe. 2008. MyD88-dependent pathway in T cells directly modulates the expansion of colitogenic CD4+ T cells in chronic colitis. J. Immunol. 180: 5291-5299
45. Zhou, L., M. M. Chong, and D. R. Littman. 2009. Plasticity of CD4+ T cell lineage differentiation. Immunity 30: 646-655
46. Weaver, C. T., L. E. Harrington, P. R. Mangan, M. Gavrieli, and K. M. Murphy. 2006. Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 24: 677-688
47. Wei, L., A. Laurence, and J. J. O'Shea. 2008. New insights into the roles of Stat5a/b and Stat3 in T cell development and differentiation. Semin. Cell Dev. Biol. 19: 394-400
48. Park, J. S., M. A. Lim, M. L. Cho, J. G. Ryu, Y. M. Moon, J. Y. Jhun, J. K. Byun, E. K. Kim, S. Y. Hwang, J. H. Ju, et al. 2013. p53 controls autoimmune arthritis via STAT-mediated regulation of the Th17 cell/Treg cell balance in mice. Arthritis Rheum. 65: 949-959
49. Mathur, A. N., H. C. Chang, D. G. Zisoulis, G. L. Stritesky, Q. Yu, J. T. O'Malley, R. Kapur, D. E. Levy, G. S. Kansas, and M. H. Kaplan. 2007. Stat3 and Stat4 direct development of IL-17-secreting Th cells. J. Immunol. 178: 4901-4907
50. Yang, X. O., A. D. Panopoulos, R. Nurieva, S. H. Chang, D. Wang, S. S. Watowich, and C. Dong. 2007. STAT3 regulates cytokine-mediated generation of inflammatory helper T cells. J. Biol. Chem. 282: 9358-9363
51. Laurence, A., C. M. Tato, T. S. Davidson, Y. Kanno, Z. Chen, Z. Yao, R. B. Blank, F. Meylan, R. Siegel, L. Hennighausen, et al. 2007. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity 26: 371-381
52. Taleb, S., M. Romain, B. Ramkhelawon, C. Uyttenhove, G. Pasterkamp, O. Herbin, B. Esposito, N. Perez, H. Yasukawa, J. Van Snick, et al. 2009. Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis. J. Exp. Med. 206: 2067-2077
53. Chen, Z., A. Laurence, Y. Kanno, M. Pacher-Zavisin, B. M. Zhu, C. Tato, A. Yoshimura, L. Hennighausen, and J. J. O'Shea. 2006. Selective regulatory function of Socs3 in the formation of IL-17-secreting T cells. Proc. Natl. Acad. Sci. USA 103: 8137-8142
54. Eberle, M. E., and A. H. Dalpke. 2012. Dectin-1 stimulation induces suppressor of cytokine signaling 1, thereby modulating TLR signaling and T cell responses. J. Immunol. 188: 5644-5654
55. Drake, M. G., G. D. Scott, B. J. Proskocil, A. D. Fryer, D. B. Jacoby, and E. H. Kaufman. 2013. Toll-like receptor 7 rapidly relaxes human airways. Am. J. Respir. Crit. Care Med. 188: 664-672
56. Hemmi, H., T. Kaisho, O. Takeuchi, S. Sato, H. Sanjo, K. Hoshino, T. Horiuchi, H. Tomizawa, K. Takeda, and S. Akira. 2002. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Immunol. 3: 196-200
57. Lee, J., T. H. Chuang, V. Redecke, L. She, P. M. Pitha, D. A. Carson, E. Raz, and H. B. Cottam. 2003. Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: activation of Toll-like receptor 7. Proc. Natl. Acad. Sci. USA 100: 6646-6651
58. Butchi, N. B., S. Pourciau, M. Du, T. W. Morgan, and K. E. Peterson. 2008. Analysis of the neuroinflammatory response to TLR7 stimulation in the brain: comparison of multiple TLR7 and/or TLR8 agonists. J. Immunol. 180: 7604-7612
59. Adner, M., M. Starkhammar, S. K. Georén, S. E. Dahlén, and L. O. Cardell. 2013. Toll-like receptor (TLR) 7 decreases and TLR9 increases the airway responses in mice with established allergic inflammation. Eur. J. Pharmacol. 718: 544-551
60. Aryan, Z., S. T. Holgate, D. Radzioch, and N. Rezaei. 2014. A new era of targeting the ancient gatekeepers of the immune system: toll-like agonists in the treatment of allergic rhinitis and asthma. Int. Arch. Allergy Immunol. 164: 46-63
61. Hayashi, T., S. Yao, B. Crain, M. Chan, R. I. Tawatao, C. Gray, L. Vuong, F. Lao, H. B. Cottam, D. A. Carson, and M. Corr. 2012. Treatment of autoimmune inflammation by a TLR7 ligand regulating the innate immune system. PLoS One 7: e45860
62. Bishop, G. A., L. M. Ramirez, M. Baccam, L. K. Busch, L. K. Pederson, and M. A. Tomai. 2001. The immune response modifier resiquimod mimics CD40- induced B cell activation. Cell. Immunol. 208: 9-17
63. Mann, M. K., A. Ray, S. Basu, C. L. Karp, and B. N. Dittel. 2012. Pathogenic and regulatory roles for B cells in experimental autoimmune encephalomyelitis. Autoimmunity 45: 388-399